Image Source:
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD. Below is how each constituent stock performed last week, in descending order, and MTD, and any recent news, commentary, and/or analysis on each company:
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Latest News, Commentary and/or Analysis:
- None
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Latest News, Commentary and/or Analysis:
- Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Latest News, Commentary and/or Analysis:
- MindMed Announces Business Update and Anticipated Milestones for 2024
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Latest News, Commentary and/or Analysis:
- None
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Latest News, Commentary and/or Analysis:
-
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
-
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
SummaryThe munKNEE Psychedelic Drug Stocks Index went UP 16.7% last week and is now up 11.7% MTD.More By This Author:
